Bone marrow-derived mesenchymal stem cells for high-metastatic potential hepatocellular carcinoma

doi:10.3969/j.issn.2095-4344.2013.49.006

Abstract

Abstract:

BACKGROUND: Bone marrow mesenchymal stem cells have the chemotaxis and homing role that promotes immune system reconstruction, eliminate residual lesions and prevent recurrence in patients.
OBJECTIVE: To observe therapeutic effect of human bone marrow mesenchymal stem cells transplantation into high-metastatic potential hepatocellular carcinoma animal models on metastatic potential of high-metastatic potential hepatocellular carcinoma.
METHODS: Nude mouse models of high-metastatic potential hepatocellular carcinoma were established in vivo. In the experimental group, 5×105 cells were injected via the tail vein on day 7 after tumor inoculation, twice a week. In the control group, cell culture medium, 0.2 mL per mouse, was injected by the tail vein. After the start of the experiment, tumor volume was measured every 4 days. After tumor inoculation for 14 days, 21 days, 28 days, 35 days, 42 days, animal models were sacrificed, and then tumor mass and body mass were recorded to calculate the inhibition rate. PCR was employed to detect osteopontin, bone sialoprotein, and integrin α Ⅴ mRNA expression, as well as bcl-2, bax, caspase3 mRNA expression.
RESULTS AND CONCLUSION: The inhibition rate of tumor mass showed the best results in week 3. As time went on, the tumor inhibition rate was gradually decreased. Metastasis-related biological factors showed a gradual down-regulated trend, indicating the polarization of tumor apoptotic indexes, that is, anti-apoptotic factor, bcl-2, showed a decreasing trend, while apoptotic factors, bax and caspase3, appeared to have a gradually increased trend. These findings suggest that human bone marrow mesenchymal stem cells effects to inhibit high-metastatic potential hepatocellular carcinoma animal models appear to vary with time. After human bone marrow mesenchymal stem cells transplantation for 3 weeks, the inhibition performance on high-metastatic potential hepatocellular carcinoma is the best, and then it weakens with time. Human bone marrow mesenchymal stem cells are found to inhibit the metastatic potential of hepatocellular carcinoma.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: stem cells, tumor, mesenchymal stem cells, bone morrow, liver neoplasms, models, animal

CLC Number:

R394.2

Li Tian-ran, Du Xiang-ke, Song Bin, Wei Zheng-mao, Huo Tian-long. Bone marrow-derived mesenchymal stem cells for high-metastatic potential hepatocellular carcinoma[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(49): 8498-8504.

Figures/Tables 6

References

[1] 汤钊猷. 从肝癌看癌症临床研究[J].肿瘤,2009,29(1):1-4

[2] Petersen BE,BowenWC,Patrene KD,et al．Bone marrow as a potential source of hepatic oval cells.Science.1999; 284 (5417): 1168-1170．

[3] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.

[4] Choi D,Kim JH,Lim M ,et al.Hepatocyte-like cells from human mesenchymal stem cells engrafted in regenerating rat liver tracked with in vivo magnetic resonance imaging.Tissue Eng Part C Methods.2008;14(1):15-23．

[5] Nasir GA, Mohsin S, Khan M,et al. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. J Transl Med. 2013;11(3):78.

[6] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.

[7] Yagi H，Soto-Gutierrez A，Parekkadan B，et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 2010; 19(6): 667-679.

[8] Barzilay R, Melamed E, Offen D. Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells. 2009;27(10): 2509-2515.

[9] Choi D,Kim JH,Lim M ,et al．Hepatocyte-like cells from human mesenchymal stem cells engrafted in regenerating rat liver tracked with in vivo magnetic resonance imaging．Tissue Eng Part C Methods.2008;14(1):15-23．

[10] Wu XZ, Yu XH.Bone marrow cells: the source of hepatocellular carcinoma? Med Hypotheses. 2007;69(1): 36-42.

[11] Sato Y,Araki H,Kato J,et al.Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion．Blood. 2005;106(2):756-763.

[12] Choi D, Kim JH, Lim M, et al. Hepatocyte-like cells from human mesenchymal stem cells engrafted in regenerating rat liver tracked with in vivo magnetic resonance imaging. Tissue Eng Part C Methods. 2008;14(1):15-23.

[13] Snykers S,Vanhaecke T,Papeleu P,et al．Sequential exposure of cytokines reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-like cells．Toxicological sciences: an official journal of the Society of Toxicology.2006;94(2): 330-341.

[14] Wong RS. Mesenchymal stem cells: angels or demons? J Biomed Biotechnol. 2011;2011:459510.

[15] Patel DM, Shah J, Srivastava AS.Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int. 2013;2013(3):496218.

[16] Choi D,Kim JH,Lim M ,et al．Hepatocyte-like cells from human mesenchymal stem cells engrafted in regenerating rat liver tracked with in vivo magnetic resonance imaging.Tissue Eng Part C Methods.2008;14(1):15-23．

[17] Snykers S,Vanhaecke T,Papeleu P,et al. Sequential exposure of cytokines reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-like cells.Toxicol Sci.2006; 94(2):330-341．

[18] 姜晗防,任军.小鼠骨髓问充质干细胞接种小鼠肝癌组织诱发肝癌细胞坏死[J].北京大学学报:医学版,2008,40(5):435-458.

[19] Barzilay R, Melamed E, Offen D. Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells. 2009; 27(10): 2509-2515.

[20] Sun XY, Nong J, Qin K, et al. MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res. 2011;31(11):3705-3712.

[21] Kucerova L, Matuskova M, Hlubinova K, et al. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer. 2010;9:129.

[22] Aquino JB, Bolontrade MF, García MG,et al. Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. Gene Ther. 2010;17(6): 692-708.

[23] 王婷,曲迅,郑广娟,等.骨桥蛋白及其信号通路对肿瘤侵袭调控的研究进展[J].中华肿瘤防治杂志, 2008,15(5):393-395.

[24] Giannelli G,Bergamini C．Human hepatoccllular carcinoma require both alpha3beta1 integrin and matriMetalloproteinases activity for migration and invasion. Lab Invest. 2001;81(4):6l3-627.

[25] Fransvea E, Mazzocca A, Antonaci S, et al. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology. 2009;49(3):839-850.

[26] 王艳红,李立新,孙瑞霞,等.αvβ3抗体对人肝癌细胞系MHCC97的粘附抑制作用[J].中华实验外科杂志,2006, 23(5): 634.

[27] Li GC, Ye QH, Dong QZ, et al. Mesenchymal stem cells seldomly fuse with hepatocellular carcinoma cells and are mainly distributed in the tumor stroma in mouse models. Oncol Rep. 2013;29(2):713-719.

[28] Choi D,Kim JH,Lim M ,et al．Hepatocyte-like cells from human mesenchymal stem cells engrafted in regenerating rat liver tracked with in vivo magnetic resonance imaging．Tissue Eng Part C Methods.2008;14(1):15-23．

[29] 李天然,杜湘珂,宋斌,等.经基因修饰的骨髓间充质干细胞对高低转移潜能肝癌细胞干预的实验研究[J].胃肠病学与肝病学杂志, 2013.

[30] Brinkmann U, Mueller RH, Babel W. The growth rate-limiting reaction in methanol-assimilating yeasts. FEMS Microbiol Rev. 1990;7(3-4):261-265.